Update on novel monoclonal antibodies and immunoconjugates for the treatment of lymphoproliferative disorders

Future Oncology

Volumn 7, Issue 8, 2011, Pages 963-979

  Derby, Lyudmyla ^a   Czuczman, Myron S ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

CD20; immunoconjugate; lymphoma; monoclonal antibody

Indexed keywords

ALEMTUZUMAB; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; BENDAMUSTINE; BL 22; BLINATUMOMAB; BRENTUXIMAB VEDOTIN; CAT 3888; CAT 8015; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTOXB20G; DACETUZUMAB; DOXORUBICIN; EPRATUZUMAB; FLUDARABINE; GALIXIMAB; HA 22; INOTUZUMAB OZOGAMICIN; LUCATUMUMAB; LUMILIXIMAB; MAPATUMUMAB; MONOCLONAL ANTIBODY; MOXETUMOMAB PASUDOTOX; OBINUTUZUMAB; OCRELIZUMAB; OFATUMUMAB; PREDNISONE; RITUXIMAB; SGN 30; TRU 015; UNCLASSIFIED DRUG; VELTUZUMAB; VINCRISTINE;

ADVERSE DRUG REACTION; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ASTHENIA; B CELL LYMPHOMA; BIOENGINEERING; BLOOD TOXICITY; CANCER RESEARCH; CANCER SURVIVAL; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CONFUSION; CONJUNCTIVITIS; CONVULSION; CYTOPENIA; DIARRHEA; DISORIENTATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; EDEMA; FATIGUE; FOLLICULAR LYMPHOMA; FOOD AND DRUG ADMINISTRATION; HAIRY CELL LEUKEMIA; HEADACHE; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; HYPOALBUMINEMIA; INFECTION; INFUSION RELATED REACTION; INJECTION SITE REACTION; LARGE CELL LYMPHOMA; LEUKOPENIA; LYMPHOCYTOPENIA; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; MYALGIA; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PERIPHERAL NEUROPATHY; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SOLID TUMOR; SPEECH DISORDER; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; TREMOR; UNITED STATES;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOCONJUGATES; LYMPHOPROLIFERATIVE DISORDERS; MOLECULAR TARGETED THERAPY; T-LYMPHOCYTES; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 80051722000     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.11.79     Document Type: Review

References (127)

1. Strebhardt K, Ullrich A. Paul Ehrlich's magic bullet concept: 100 years of progress. Nat. Rev. Cancer 8(6), 473-480 (2008). (Pubitemid 351752547)
2. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256(5517), 495-497 (1975).
3. McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16(8), 2825-2833 (1998). nn Pivotal trial of rituximab that led to its US FDA approval. (Pubitemid 28363048)
4. Riley JK, Sliwkowski MX. CD20: A gene in search of a function. Semin. Oncol. 27(6 Suppl. 12), 17-24 (2000). (Pubitemid 32164592)
5. Beers SA, Chan CH, French RR, Cragg MS, Glennie MJ. CD20 as a target for therapeutic type I and II monoclonal antibodies. Semin. Hematol. 47(2), 107-114 (2010).
6. Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr. Dir. Autoimmun. 8, 140-174 (2005).
7. Deans JP, Robbins SM, Polyak MJ, Savage JA. Rapid redistribution of CD20 to a low density detergent-insoluble membrane compartment. J. Biol. Chem. 273(1), 344-348 (1998). (Pubitemid 28042215)
8. Robak T, Robak E. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies. Biodrugs 25(1), 13-25 (2011).
9. Chan HT, Hughes D, French RR et al. CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. Cancer Res. 63(17), 5480-5489 (2003). (Pubitemid 37139867)
10. Taylor RP, Lindorfer MA. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr. Opin. Immunol. 20(4), 444-449 (2008).
11. Golay J, Zaffaroni L, Vaccari T et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 95(12), 3900-3908 (2000). (Pubitemid 30412866)
12. Lefebvre ML, Krause SW, Salcedo M, Nardin A. Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: Mechanism of antibody-dependent cellular cytotoxicity and impact of human serum. J. Immunother. 29(4), 388-397 (2006). (Pubitemid 44288951)
13. Byrd JC, Kitada S, Flinn IW et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: Evidence of caspase activation and apoptosis induction. Blood 99(3), 1038-1043 (2002). (Pubitemid 34525569)
14. Wilson WH. Chemotherapy sensitization by rituximab: Experimental and clinical evidence. Semin. Oncol. 27(6 Suppl. 12), 30-36 (2000). (Pubitemid 32164594)
15. Davis TA, Grillo-Lopez AJ, White CA et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment. J. Clin. Oncol. 18(17), 3135-3143 (2000).
16. Stolz C, Schuler M. Molecular mechanisms of resistance to rituximab and pharmacologic strategies for its circumvention. Leuk. Lymphoma 50(6), 873-885 (2009).
17. Bello C, Sotomayor EM. Monoclonal antibodies for B-cell lymphomas: Rituximab and beyond. Hematology Am. Soc. Hematol. Educ. Program 233-242 (2007).
18. Cartron G, Dacheux L, Salles G et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgRIIIa gene. Blood 99(3), 754-758 (2002). (Pubitemid 34525533)
19. Stein R, Qu Z, Chen S et al. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clin. Cancer Res. 10(8), 2868-2878 (2004). (Pubitemid 38509167)
20. Goldenberg DM, Rossi EA, Stein R et al. Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood 113(5), 1062-1070 (2009).
21. Milani C, Castillo J. Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura. Curr. Opin. Mol. Ther. 11(2), 200-207 (2009).
22. Negrea OG, Elstrom R, Allen SL et al. Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin lymphoma. Haematologica 96(4), 567-573 (2011).
23. Morschhauser F, Leonard JP, Fayad L et al. Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: Phase I/II results. J. Clin. Oncol. 27(20), 3346-3353 (2009).
24. Du J, Yang H, Guo Y, Ding J. Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20. Mol. Immunol. 46(11-12), 2419-2423 (2009).
25. Teeling JL, French RR, Cragg MS et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 104(6), 1793-1800 (2004). (Pubitemid 39202289)
26. Teeling JL, Mackus WJ, Wiegman LJ et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J. Immunol. 177(1), 362-371 (2006). (Pubitemid 43939148)
27. Bleeker WK, Munk ME, Mackus WJ et al. Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody. Br. J. Haematol. 140(3), 303-312 (2008).
28. Hagenbeek A, Gadeberg O, Johnson P et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: Results of a Phase 1/2 trial. Blood 111(12), 5486-5495 (2008).
29. Coiffier B, Lepretre S, Pedersen LM et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: A Phase 1-2 study. Blood 111(3), 1094-1100 (2008). (Pubitemid 351213387)
30. Coiffier B, Losic N, Ronn BB et al. Pharmacokinetics and pharmacokinetic/pharmacodynamic associations of ofatumumab, a human monoclonal CD20 antibody, in patients with relapsed or refractory chronic lymphocytic leukaemia: A Phase 1-2 study. Br. J. Haematol. 150(1), 58-71 (2010).
31. Wierda WG, Kipps TJ, Mayer J et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J. Clin. Oncol. 28(10), 1749-1755 (2010). nn Demonstrates activity of a novel second-generation anti-CD20 monoclonal antibody (ofatumumab), which led to the FDA approval of its use in chronic lymphocytic leukemia.
32. Kausar F, Mustafa K, Sweis G et al. Ocrelizumab: A step forward in the evolution of B-cell therapy. Expert Opin. Biol. Ther. 9(7), 889-895 (2009).
33. Morschhauser F, Marlton P, Vitolo U et al. Results of a Phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma. Ann. Oncol. 21(9), 1870-1876 (2010).
34. Mossner E, Brunker P, Moser S et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 115(22), 4393-4402 (2010).
35. Umana P, Moessner E, Bruenker P et al. Novel 3rd generation humanized type II CD20 antibody with glycoengineered Fc and modified elbow hinge for enhanced ADCC and superior apoptosis induction. Blood 108(11), Abstract 229 (2006).
36. Alduaij W, Ivanov A, Honeychurch J et al. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood 117(17), 4519-4529 (2011). nn Exciting information regarding type II anti-CD20 monoclonal antibodies that are currently in clinical trials.
37. Dalle S, Reslan L, Besseyre De Horts T et al. Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101. Mol. Cancer Ther. 10(1), 178-185 (2011).
38. Patz M, Isaeva P, Forcob N et al. Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells. Br. J. Haematol. 152(3), 295-306 (2011).
39. Niederfellner G, Lammens A, Schwaiger M, et al. Crystal structure analysis reveals that the novel type II anti-CD20 antibody GA101 interacts with a similar epitope as rituximab and ocrelizumab but in a fundamentally different way. Blood 114(22), Abstract 3726 (2009).
40. Salles G, Morschhauser F, Lamy T et al. Phase I study of RO5072759 (GA101) in patients with relapsed/refractory CD20+ non-Hodgkin lymphoma (NHL). Blood 114(22), Abstract 1704 (2009).
41. Morschhauser F, Cartron G, Lamy T. Phase I study of RO5072759 (GA101) in relapsed/refractory chronic lymphocytic leukemia. Blood 114, Abstract 884 (2009).
42. Sato S, Tuscano JM, Inaoki M, Tedder TF. CD22 negatively and positively regulates signal transduction through the B lymphocyte antigen receptor. Semin. Immunol. 10(4), 287-297 (1998). (Pubitemid 28375304)
43. Vitetta ES, Stone M, Amlot P et al. Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res. 51(15), 4052-4058 (1991).
44. Otipoby KL, Andersson KB, Draves KE et al. CD22 regulates thymus-independent responses and the lifespan of B cells. Nature 384(6610), 634-637 (1996).
45. Leonard JP, Coleman M, Ketas JC et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J. Clin. Oncol. 21(16), 3051-3059 (2003). (Pubitemid 46606284)
46. Leonard JP, Coleman M, Ketas JC et al. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: Phase I/II clinical trial results. Clin. Cancer Res. 10(16), 5327-5334 (2004). (Pubitemid 39100467)
47. Strauss SJ, Morschhauser F, Rech J et al. Multicenter Phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. J. Clin. Oncol. 24(24), 3880-3886 (2006). (Pubitemid 46630735)
48. Micallef IN, Kahl BS, Maurer MJ et al. A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma. Cancer 107(12), 2826-2832 (2006). (Pubitemid 44937036)
49. Micallef IN, Maurer MJ, Nikcevich DA et al. Final results of NCCTG N0489: Epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma. J. Clin. Oncol. 27(15), Abstract 8508 (2009).
50. Denardo GL, Schlom J, Buchsbaum DJ et al. Rationales, evidence, and design considerations for fractionated radioimmunotherapy. Cancer 94(4 Suppl.), 1332-1348 (2002). (Pubitemid 34150897)
51. Sharkey RM, Behr TM, Mattes MJ et al. Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22. Cancer Immunol. Immunother. 44(3), 179-188 (1997). (Pubitemid 27278391)
52. Griffiths GL, Govindan SV, Sharkey RM, Fisher DR, Goldenberg DM. 90Y-DOTA-hLL2: An agent for radioimmunotherapy of non-Hodgkin's lymphoma. J. Nucl. Med. 44(1), 77-84 (2003). (Pubitemid 36077716)
53. Linden O, Hindorf C, Cavallin-Stahl E et al. Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab. Clin. Cancer Res. 11(14), 5215-5222 (2005). (Pubitemid 41003709)
54. Morschhauser F, Kraeber-Bodere F, Wegener WA et al. High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: Results of a multicenter, Phase I/II study in non-Hodgkin's lymphoma. J. Clin. Oncol. 28(23), 3709-3716 (2010). nn Demonstrates the significant clinical activity of an anti-CD22 radiolabeled antibody. The radiolabeled anti-CD22 antibody is internalized once it is bound to its target (i.e., to CD22).
55. Dijoseph JF, Armellino DC, Boghaert ER et al. Antibody-targeted chemotherapy with CMC-544: A CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood 103(5), 1807-1814 (2004). (Pubitemid 38268977)
56. Dijoseph JF, Goad ME, Dougher MM et al. Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma. Clin. Cancer Res. 10(24), 8620-8629 (2004). (Pubitemid 40053430)
57. Advani A, Coiffier B, Czuczman MS et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: Results of a Phase I study. J. Clin. Oncol. 28(12), 2085-2093 (2010).
58. Dang NH, Smith MR, Offner F et al. Anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) + rituximab: Clinical activity including survival in patients with recurrent/refractory follicular or 'aggressive' lymphoma. Blood 114(22), Abstract 584 (2009).
59. Kreitman RJ, Wilson WH, Bergeron K et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N. Engl. J. Med. 345(4), 241-247 (2001). (Pubitemid 32695063)
60. Kreitman RJ, Stetler-Stevenson M, Margulies I et al. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J. Clin. Oncol. 27(18), 2983-2990 (2009).
61. Kreitman RJ, Wilson WH, Stetler-Stevenson M, Noel P, Fitzgerald DJ, Pastan I. Long term results of BL22 (CAT-3888) in multiply relapsed hairy cell leukemia. Blood 114, Abstract 3442 (2009).
62. Alderson RF, Kreitman RJ, Chen T et al. CAT-8015: A second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignancies. Clin. Cancer Res. 15(3), 832-839 (2009).
63. Kreitman RJ, Tallman MS, Coutre S et al. A Phase 1 study of moxetumomab pasudotox, an anti-CD22 recombinant immunotoxin, in relapsed/refractory hairy cell leukemia (HCL): Updated results. Blood 116, Abstract 2516 (2010).
64. Liu YJ, Cairns JA, Holder MJ et al. Recombinant 25-kDa CD23 and interleukin 1 a promote the survival of germinal center B cells: Evidence for bifurcation in the development of centrocytes rescued from apoptosis. Eur. J. Immunol. 21(5), 1107-1114 (1991).
65. Lopez-Matas M, Rodriguez-Justo M, Morilla R, Catovsky D, Matutes E. Quantitative expression of CD23 and its ligand CD21 in chronic lymphocytic leukemia. Haematologica 85(11), 1140-1145 (2000).
66. Newman R, Alberts J, Anderson D et al. 'Primatization' of recombinant antibodies for immunotherapy of human diseases: A macaque/human chimeric antibody against human CD4. Biotechnology (NY) 10(11), 1455-1460 (1992).
67. Pathan NI, Chu P, Hariharan K, Cheney C, Molina A, Byrd J. Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines. Blood 111(3), 1594-1602 (2008). (Pubitemid 351213450)
68. Byrd JC, O'Brien S, Flinn IW et al. Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clin. Cancer Res. 13(15 Pt 1), 4448-4455 (2007). (Pubitemid 47219713)
69. Byrd JC, Kipps TJ, Flinn IW et al. Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Blood 115(3), 489-495 (2010).
70. Wierda W, O'Brien S, Wen S et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J. Clin. Oncol. 23(18), 4070-4078 (2005). nn This regimen has very high and durable response rates in relapsed/refractory chronic lymphocytic leukemia, but also in treatment-naive patients. (Pubitemid 46211312)
71. Peach RJ, Bajorath J, Naemura J et al. Both extracellular immunoglobin-like domains of CD80 contain residues critical for binding T cell surface receptors CTLA-4 and CD28. J. Biol. Chem. 270(36), 21181-21187 (1995).
72. Dorfman DM, Schultze JL, Shahsafaei A et al. In vivo expression of B7-1 and B7-2 by follicular lymphoma cells can prevent induction of T-cell anergy but is insufficient to induce significant T-cell proliferation. Blood 90(11), 4297-4306 (1997). (Pubitemid 27508435)
73. Suvas S, Singh V, Sahdev S, Vohra H, Agrewala JN. Distinct role of CD80 and CD86 in the regulation of the activation of B cell and B cell lymphoma. J. Biol. Chem. 277(10), 7766-7775 (2002). (Pubitemid 34968223)
74. Hariharan K, Anderson D, Leigh B et al. Therapeutic activity of IDEC-114 (anti-CD80) and rituximab (Rituxan®) in B-cell lymphoma. Blood 98(608A), Abstract 2549 (2001).
75. Czuczman MS, Thall A, Witzig TE et al. Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J. Clin. Oncol. 23(19), 4390-4398 (2005). (Pubitemid 46207013)
76. Leonard JP, Friedberg JW, Younes A et al. A Phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. Ann. Oncol. 18(7), 1216-1223 (2007). (Pubitemid 47244369)
77. Friedberg JW, Younes A, Fisher DC et al. Durable responses in patients treated with galiximab (anti-CD80) in combination with rituximab for relapsed or refractory follicular lymphoma: Long-term follow-up of a Phase II clinical trial. Blood 112(11), Abstract 1004 (2008).
78. Czuczman MS, Leonard JP, Johnson JL et al. FLIPI score is applicable and predictive of response to upfront immunotherapy in CALGB 50402: Phase II trial of extended induction galiximab ([G] anti-CD80 monoclonal antibody) plus rituximab [R]. Blood 112(11), Abstract 1003 (2008).
79. Bence-Bruckler I, Macdonald D, Stiff PJ et al. A Phase 2, double-blind, placebo-controlled trial of rituximab + galiximab vs rituximab + placebo in advanced follicular non-Hodgkin's lymphoma (NHL). Blood 116(21), Abstract 428 (2010).
80. Uckun FM, Gajl-Peczalska K, Myers DE, Jaszcz W, Haissig S, Ledbetter JA. Temporal association of CD40 antigen expression with discrete stages of human B-cell ontogeny and the efficacy of anti-CD40 immunotoxins against clonogenic B-lineage acute lymphoblastic leukemia as well as B-lineage non-Hodgkin's lymphoma cells. Blood 76(12), 2449-2456 (1990).
81. Gruss HJ, Herrmann F, Gattei V, Gloghini A, Pinto A, Carbone A. CD40/CD40 ligand interactions in normal, reactive and malignant lympho-hematopoietic tissues. Leuk. Lymphoma 24(5-6), 393-422 (1997). (Pubitemid 27182198)
82. Gruss HJ, Hirschstein D, Wright B et al. Expression and function of CD40 on Hodgkin and Reed-Sternberg cells and the possible relevance for Hodgkin's disease. Blood 84(7), 2305-2314 (1994). (Pubitemid 24296393)
83. Law CL, Gordon KA, Collier J et al. Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40. Cancer Res. 65(18), 8331-8338 (2005). (Pubitemid 41330598)
84. Lewis TS, McCormick RS, Stone IJ et al. Proapoptotic signaling activity of the anti-CD40 monoclonal antibody dacetuzumab circumvents multiple oncogenic transformation events and chemosensitizes NHL cells. Leukemia 25(6), 1007-1016 (2011).
85. Advani R, Forero-Torres A, Furman RR et al. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. J. Clin. Oncol. 27(26), 4371-4377 (2009).
86. Advani R, Vos SD, Ansell SM et al. A Phase 2 clinical trial of SGN-40 monotherapy in relapsed diffuse large B-cell lymphoma. Blood 112(11), Abstract 1000 (2008).
87. Forero-Torres A, Bartlett NL, Nasta SD et al. A Phase 1b clinical trial of dacetuzumab in combination with rituximab and gemcitabine: Multiple responses observed in patients with relapsed diffuse large B-cell lymphoma. Blood 114(22), Abstract 586 (2009).
88. Agura E, Niesvizky R, Matous J et al. Dacetuzumab (SGN-40), lenalidomide, and weekly dexamethasone in relapsed or refractory multiple myeloma: Multiple responses observed in a Phase 1b study. Blood 114(22), Abstract 2870 (2009).
89. Luqman M, Klabunde S, Lin K et al. The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells. Blood 112(3), 711-720 (2008).
90. Falini B, Pileri S, Pizzolo G et al. CD30 (Ki-1) molecule: A new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 85(1), 1-14 (1995).
91. Durkop H, Latza U, Hummel M, Eitelbach F, Seed B, Stein H. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell 68(3), 421-427 (1992).
92. Matsumoto K, Terakawa M, Miura K, Fukuda S, Nakajima T, Saito H. Extremely rapid and intense induction of apoptosis in human eosinophils by anti-CD30 antibody treatment in vitro. J. Immunol. 172(4), 2186-2193 (2004). (Pubitemid 38182365)
93. Bartlett NL, Younes A, Carabasi MH et al. A Phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood 111(4), 1848-1854 (2008). (Pubitemid 351451492)
94. Forero-Torres A, Leonard JP, Younes A et al. A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br. J. Haematol. 146(2), 171-179 (2009).
95. Younes A, Bartlett NL, Leonard JP et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N. Engl. J. Med. 363(19), 1812-1821 (2010). nn Presents a very exciting drug immunoconjugate that targets CD30 and will be evaluated by the FDA later in 2011. Represents an important antitumor agent for Hodgkin lymphoma and anaplastic non-Hodgkin lymphoma.
96. Chen R, Gopal A, Smith S et al. Results of a pivotal Phase 2 study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma. Blood 116, Abstract 283 (2010).
97. Shustov A, Advani R, Brice P et al. Complete remissions with brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood 116(21), Abstract 961 (2010).
98. Ansell SM, Horwitz SM, Engert A et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J. Clin. Oncol. 25(19), 2764-2769 (2007). (Pubitemid 47123185)
99. Blum KA, Smith MR, Fung HC et al. Phase I study of an anti-CD30 Fc engineered humanized monoclonal antibody in Hodgkin lymphoma (HL) or anaplastic large cell lymphoma (ALCL) patients: Safety, pharmacokinetics (PK), immunogenicity, and efficacy. J. Clin. Oncol. 27(15 Suppl.), Abstract 8531 (2009).
100. Wiezorek J, Holland P, Graves J. Death receptor agonists as a targeted therapy for cancer. Clin. Cancer Res. 16(6), 1701-1708 (2010).
101. Zang DY, Goodwin RG, Loken MR, Bryant E, Deeg HJ. Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: Effects on in vitro hemopoiesis. Blood 98(10), 3058-3065 (2001).
102. Hague A, Hicks DJ, Hasan F et al. Increased sensitivity to TRAIL-induced apoptosis occurs during the adenoma to carcinoma transition of colorectal carcinogenesis. Br. J. Cancer 92(4), 736-742 (2005). (Pubitemid 40460611)
103. Call JA, Eckhardt SG, Camidge DR. Targeted manipulation of apoptosis in cancer treatment. Lancet Oncol. 9(10), 1002-1011 (2008).
104. Pukac L, Kanakaraj P, Humphreys R et al. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br. J. Cancer 92(8), 1430-1441 (2005). (Pubitemid 40705010)
105. Maddipatla S, Hernandez-Ilizaliturri FJ, Knight J, Czuczman MS. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20. Clin. Cancer Res. 13(15 Pt 1), 4556-4564 (2007). (Pubitemid 47219726)
106. Daniel D, Yang B, Lawrence DA et al. Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts. Blood 110(12), 4037-4046 (2007). (Pubitemid 350248460)
107. Tolcher AW, Mita M, Meropol NJ et al. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J. Clin. Oncol. 25(11), 1390-1395 (2007). (Pubitemid 46706887)
108. Greco FA, Bonomi P, Crawford J et al. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer 61(1), 82-90 (2008).
109. Hotte SJ, Hirte HW, Chen EX et al. A Phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. Clin. Cancer Res. 14(11), 3450-3455 (2008).
110. Mom CH, Verweij J, Oldenhuis CN et al. Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: A Phase I study. Clin. Cancer Res. 15(17), 5584-5590 (2009).
111. Trarbach T, Moehler M, Heinemann V et al. Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer. Br. J. Cancer 102(3), 506-512 (2010).
112. Younes A, Vose JM, Zelenetz AD et al. A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma. Br. J. Cancer 103(12), 1783-1787 (2010).
113. Wahlin BE, Sander B, Christensson B, Kimby E. CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma. Clin. Cancer Res. 13(2 Pt 1), 388-397 (2007). (Pubitemid 46225341)
114. Nagorsen D, Bargou R, Ruttinger D, Kufer P, Baeuerle PA, Zugmaier G. Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab. Leuk. Lymphoma 50(6), 886-891 (2009).
115. Brischwein K, Parr L, Pflanz S et al. Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class. J. Immunother. 30(8), 798-807 (2007). (Pubitemid 350295358)
116. Baeuerle PA, Kufer P, Bargou R. BiTE: Teaching antibodies to engage T-cells for cancer therapy. Curr. Opin. Mol. Ther. 11(1), 22-30 (2009).
117. Dreier T, Baeuerle PA, Fichtner I et al. T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3-bispecific single-chain antibody construct. J. Immunol. 170(8), 4397-4402 (2003). (Pubitemid 36428210)
118. Bargou R, Leo E, Zugmaier G et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321(5891), 974-977 (2008).
119. D'Argouges S, Wissing S, Brandl C et al. Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells. Leuk. Res. 33(3), 465-473 (2009).
120. Gill DS, Damle NK. Biopharmaceutical drug discovery using novel protein scaffolds. Curr. Opin. Biotechnol. 17(6), 653-658 (2006). (Pubitemid 44802987)
121. Hayden-Ledbetter MS, Cerveny CG, Espling E et al. CD20-directed small modular immunopharmaceutical, TRU-015, depletes normal and malignant B cells. Clin. Cancer Res. 15(8), 2739-2746 (2009).
122. Quintas-Cardama A, Wierda W, O'Brien S. Investigational immunotherapeutics for B-cell malignancies. J. Clin. Oncol. 28(5), 884-892 (2010).
123. Burge DJ, Bookbinder SA, Kivitz AJ, Fleischmann RM, Shu C, Bannink J. Pharmacokinetic and pharmacodynamic properties of TRU-015, a CD20-directed small modular immunopharmaceutical protein therapeutic, in patients with rheumatoid arthritis: A Phase I, open-label, dose-escalation clinical study. Clin. Ther. 30(10), 1806-1816 (2008).
124. Robak T, Robak P, Smolewski P. TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies. Curr. Opin. Investig. Drugs 10(12), 1383-1390 (2009).
125. Baum PR, Cerveny C, Gordon B. Evaluation of the effect of TRU-016, an anti-CD37 directed SMIP in combination with other therapeutic drugs in models of non-Hodgkin's lymphoma. J. Clin. Oncol. 27(15 Suppl.), Abstract 8571 (2009).
126. Algate PA, Wiens J, Nilsson C et al. TRU-016, an anti-CD37 SMIPTM biologic, in combination with other therapeutic drugs in models of non-Hodgkin's lymphoma. Blood 116(3931), Absract 3931 (2010).
127. Furman RR, Andritsos L, Flinn IW et al. Phase 1 dose escalation study of TRU-016, an anti-CD37 SMIP™ protein in relapsed and refractory CLL. Blood 116(21), Abstract 56 (2010).